Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to -$45.1 million.

  • Maravai Lifesciences Holdings' Net Income towards Common Stockholders rose 7387.32% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year increase of 3391.36%. This contributed to the annual value of -$259.6 million for FY2024, which is 8762.2% down from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' Net Income towards Common Stockholders stood at -$45.1 million, which was up 7387.32% from -$69.8 million recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Net Income towards Common Stockholders peaked at $156.7 million during Q2 2022, and registered a low of -$172.5 million during Q3 2024.
  • In the last 5 years, Maravai Lifesciences Holdings' Net Income towards Common Stockholders had a median value of -$11.9 million in 2023 and averaged $20.7 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 922711.51% in 2021, then plummeted by 158249.26% in 2024.
  • Maravai Lifesciences Holdings' Net Income towards Common Stockholders (Quarter) stood at $127.1 million in 2021, then tumbled by 31.22% to $87.4 million in 2022, then crashed by 225.8% to -$110.0 million in 2023, then surged by 58.11% to -$46.1 million in 2024, then rose by 2.19% to -$45.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$45.1 million in Q3 2025, compared to -$69.8 million in Q2 2025 and -$52.9 million in Q1 2025.